Rx Importation Would Lead To Two Drug Classes, FDA Chief Counsel Troy Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Separate classes of drugs would result from the complexity associated with developing a system to certify the safety of imports, Troy asserts. The only alternative to separate drug classes would be a “favored nations” approach to drug approvals.